New HIV prevention shot gets a boost: enzyme may make injections last longer

NCT ID NCT05418868

Recruiting now Disease control Sponsor: ViiV Healthcare Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This early-stage study is testing a long-acting injectable HIV prevention drug called cabotegravir, combined with an enzyme (rHuPH20) that helps the drug spread under the skin. The goal is to see if this combination is safe and how the body processes it in 214 healthy adults. Researchers are also testing different doses and injection methods (under the skin or into muscle) to find the best approach for future studies.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: cabotegravir (an HIV drug) and recombinant human hyaluronidase PH20 (an enzyme that helps the drug spread under the skin)
What this could lead to: If successful, this could lead to a longer-lasting, easier-to-take injectable HIV prevention option, potentially reducing how often shots are needed.
What could go wrong: This is a very early (Phase 1) study in healthy volunteers, not people with HIV. It only tests safety and drug levels, not whether it prevents HIV. Many early-stage studies do not lead to approved treatments.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HIV INFECTIONS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

HIV infectious disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HIV INFECTIONS

Contacts and locations

Locations

GSK Investigational Site
COMPLETED

Orlando, Florida, 32806, United States
GSK Investigational Site
RECRUITING

Las Vegas, Nevada, 89113, United States
GSK Investigational Site
RECRUITING

Austin, Texas, 78744, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.